Industry watchers will be tracking closely Replimune Group Inc.’s latest attempt to secure U.S. FDA approval of its advanced melanoma candidate, RP-1 (vusolimogene oderparepvec). The company announced Friday it had reached alignment for resubmitting the twice-rejected BLA with the agency, which it said has pledged to prioritize the review.
Zhize Tongkang (Guangzhou) Biotechnology Co. Ltd. has divulged new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting claudin 6 (CLDN6) linked to a camptothecin derivative potentially useful for the treatment of cancer and fibrosis.
Anti-PD-1/PD-L1 therapy has shown success in the treatment of liver cancer and may reverse immune tolerance in chronic hepatitis B (CHB). Aligos Therapeutics Inc. has presented preclinical data on the characterization of ALG-093940, a small molecule PD-1/PD-L1 inhibitor that induces PD-L1 dimerization and degradation.
Hutchmed Ltd. has identified new antibody-drug conjugates (ADCs) comprising an antibody targeting EGFR (HER1; erbB1) linked to cytotoxic drug potentially useful for the treatment of cancer and autoimmune diseases.
Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025.
At the ongoing European Association for the Study of the Liver 2026 annual meeting in Barcelona, researchers from Oricell Therapeutics Co. Ltd. presented data on a CAR T-cell approach targeting glypican 3 (GPC3) – OriC-902 – for the treatment of GPC3+ hepatocellular carcinoma (HCC).
Kolon Life Science Inc. is developing KLS-3021, a next-generation oncolytic vaccinia virus designed to express the PH20, IL-12 and PD-1-Fc transgenes to mediate receptor-independent tumor cell killing and enhance antitumor immune responses.
Biomunex Pharmaceuticals SAS has entered into strategic collaborations with two AI-specialized companies – Gordion Bioscience Inc. and Tangramed Biotech SAS – as part of its strategy to integrate AI into its R&D activities and support the development of next-generation immunotherapies in oncology.
Kunshan Xinyunda Biotechnology Co. Ltd. has patented new antibody-drug conjugates (ADCs) consisting of humanized antibodies targeting disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) covalently linked to a payload and potentially useful for the treatment of cancer and inflammatory disorders.
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live melanoma cells, and the discovery could reshape thinking around macrophage-targeted cancer therapies and innate immunity in oncology.
RSS
